Sort
261,768 grants matching “gene therapy”
MULTICENTER CLINICAL STUDY OF ALS GENETICS
$1,094,656Northwestern University · R01 · FY2000 · NS
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,094,655Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Xenobiotic-Metabolizing Enzymes
$1,094,579Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Alleviation of ER stress as a translational strategy to curb ocular viral infections
$1,094,442Deepak Shukla · University Of Illinois At Chicago · R24 · FY2024 · EY
(Epi)genetic Risk Architectures in Opioid Dependent Brain
$1,094,363Peter Christopher Scacheri · Case Western Reserve University · R01 · FY2017 · DA
RELEVANCE OF GENOMIC ALTERATIONS IN COLORECTAL CANCER
$1,094,222Thomas Jefferson University · P01 · FY2001 · CA
Extending GWAS at the BCL11A locus to novel therapeutics for HbF induction
$1,094,197Stuart H Orkin · Dana-Farber Cancer Inst · RC2 · FY2009 · HL
CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry
$1,094,189Jose M Mejia Oneto · Shasqi, Inc. · R44 · FY2025 · CA
MOLECULAR CLASSIFICATION OF COLON TUMORS
$1,094,131Montefiore Medical Center (Bronx, Ny) · U01 · FY2003 · CA
A RESOURCE FOR MAGNETIC RESONANCE AND OPTICAL RESEARCH
$1,094,055University Of Pennsylvania · P41 · FY2003 · RR
Small Molecule Therapeutics for Renal Disease
$1,094,052Prakash Narayan · Angion Biomedica Corporation · R44 · FY2010 · DK
Depletion, Repopulation and Tolerance in Sensitized Recipients
$1,094,006Stuart Johnston Knechtle · Duke University · U19 · FY2021 · AI
Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses
$1,093,892Wayne A. Marasco · Dana-Farber Cancer Inst · R01 · FY2010 · AI
Genetic Susceptibility and Biomarkers of Platinum-related Toxicities
$1,093,680Lois B. Travis · Indiana University Indianapolis · R01 · FY2023 · CA
Molecular Therapy for CF and Genetic Diseases
$1,093,528James M Wilson · University Of Pennsylvania · P30 · FY2013 · DK
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS
$1,093,040Thomas Gaj · University Of Illinois At Urbana-Champaign · U01 · FY2024 · NS
STING agonist-expressing BCG for bladder cancer
$1,092,982Todd Wallach · Oncosting Llc · R44 · FY2023 · CA
NEI Genetic Engineering Core
$1,092,967Lijin Dong · National Eye Institute · ZIC · FY2014 · EY
Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs)
$1,092,964Jeffrey H. Price · Vala Sciences, Inc. · R44 · FY2025 · MH
Novel Small-Molecule Therapies for CF
$1,092,849Alan S Verkman · University Of California, San Francisco · P30 · FY2014 · DK
Integrated Systems Biology Approach to Diabetic Microvascular Complications
$1,092,803Frank C Brosius · University Of Michigan At Ann Arbor · R24 · FY2014 · DK
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$1,092,801Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
B-CELL TARGETED INDUCTION TO IMPROVE OUTCOMES IN PEDIATRIC LUNG TRANSPLANTATION
$1,092,701Stuart C Sweet · Washington University · U01 · FY2016 · AI
IMPROVING MUSCLE FUNCTION THROUGH GENE DELIVERY
$1,092,657University Of Pittsburgh At Pittsburgh · P01 · FY2001 · AR
Functional Validation of TDP-43 splicing repression for frontotemporal degeneration
$1,092,581Philip C Wong · Johns Hopkins University · UH3 · FY2022 · NS